tetano
Editor, Senior Moderator
Eur J Med Chem
. 2020 Jun 6;201:112527.
doi: 10.1016/j.ejmech.2020.112527. Online ahead of print.
A Promising Antiviral Candidate Drug for the COVID-19 Pandemic: A Mini-Review of Remdesivir
Chengyuan Liang[SUP] 1 [/SUP], Lei Tian[SUP] 2 [/SUP], Yuzhi Liu[SUP] 2 [/SUP], Nan Hui[SUP] 2 [/SUP], Guaiping Qiao[SUP] 2 [/SUP], Han Li[SUP] 2 [/SUP], Zhenfeng Shi[SUP] 3 [/SUP], Yonghong Tang[SUP] 4 [/SUP], Dezhu Zhang[SUP] 5 [/SUP], Xiaolin Xie[SUP] 5 [/SUP], Xu Zhao[SUP] 6 [/SUP]
Affiliations
Abstract
Remdesivir (GS-5734), a viral RNA-dependent RNA polymerase (RdRP) inhibitor that can be used to treat a variety of RNA virus infections, is expected to be an effective treatment for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. On May 1, 2020, The U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for remdesivir to treat COVID-19 patients. In light of the COVID-19 pandemic, this review presents comprehensive information on remdesivir, including information regarding the milestones, intellectual properties, anti-coronavirus mechanisms, preclinical research and clinical trials, and in particular, the chemical synthesis, pharmacology, toxicology, pharmacodynamics and pharmacokinetics of remdesivir. Furthermore, perspectives regarding the use of remdesivir for the treatment of COVID-19 are also discussed.
Keywords: Antiviral; COVID-19; Coronavirus; RdRP inhibitor; Remdesivir (GS-5734).
. 2020 Jun 6;201:112527.
doi: 10.1016/j.ejmech.2020.112527. Online ahead of print.
A Promising Antiviral Candidate Drug for the COVID-19 Pandemic: A Mini-Review of Remdesivir
Chengyuan Liang[SUP] 1 [/SUP], Lei Tian[SUP] 2 [/SUP], Yuzhi Liu[SUP] 2 [/SUP], Nan Hui[SUP] 2 [/SUP], Guaiping Qiao[SUP] 2 [/SUP], Han Li[SUP] 2 [/SUP], Zhenfeng Shi[SUP] 3 [/SUP], Yonghong Tang[SUP] 4 [/SUP], Dezhu Zhang[SUP] 5 [/SUP], Xiaolin Xie[SUP] 5 [/SUP], Xu Zhao[SUP] 6 [/SUP]
Affiliations
- PMID: 32563812
- DOI: 10.1016/j.ejmech.2020.112527
Abstract
Remdesivir (GS-5734), a viral RNA-dependent RNA polymerase (RdRP) inhibitor that can be used to treat a variety of RNA virus infections, is expected to be an effective treatment for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. On May 1, 2020, The U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for remdesivir to treat COVID-19 patients. In light of the COVID-19 pandemic, this review presents comprehensive information on remdesivir, including information regarding the milestones, intellectual properties, anti-coronavirus mechanisms, preclinical research and clinical trials, and in particular, the chemical synthesis, pharmacology, toxicology, pharmacodynamics and pharmacokinetics of remdesivir. Furthermore, perspectives regarding the use of remdesivir for the treatment of COVID-19 are also discussed.
Keywords: Antiviral; COVID-19; Coronavirus; RdRP inhibitor; Remdesivir (GS-5734).